Antengene Corporation Limited

DB:722 Stock Report

Market Cap: €60.5m

Antengene Management

Management criteria checks 2/4

Antengene's CEO is Jay Mei, appointed in Aug 2020, has a tenure of 4.42 years. total yearly compensation is CN¥16.77M, comprised of 37.8% salary and 62.2% bonuses, including company stock and options. directly owns 26% of the company’s shares, worth €15.72M. The average tenure of the management team and the board of directors is 4.4 years and 4.2 years respectively.

Key information

Jay Mei

Chief executive officer

CN¥16.8m

Total compensation

CEO salary percentage37.8%
CEO tenure4.4yrs
CEO ownership26.0%
Management average tenure4.4yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jay Mei's remuneration changed compared to Antengene's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥530m

Mar 31 2024n/an/a

-CN¥555m

Dec 31 2023CN¥17mCN¥6m

-CN¥581m

Sep 30 2023n/an/a

-CN¥628m

Jun 30 2023n/an/a

-CN¥676m

Mar 31 2023n/an/a

-CN¥639m

Dec 31 2022CN¥15mCN¥6m

-CN¥601m

Sep 30 2022n/an/a

-CN¥584m

Jun 30 2022n/an/a

-CN¥567m

Mar 31 2022n/an/a

-CN¥611m

Dec 31 2021CN¥17mCN¥5m

-CN¥656m

Compensation vs Market: Jay's total compensation ($USD2.29M) is above average for companies of similar size in the German market ($USD462.36K).

Compensation vs Earnings: Jay's compensation has increased whilst the company is unprofitable.

CEO

Jay Mei (59 yo)

4.4yrs

Tenure

CN¥16,774,000

Compensation

Dr. Jay Mei, M.D. & Ph.D. is the Founder of Antengene Corporation and serves as Chairman and Chief Executive Officer since August 18, 2020. Dr. Mei has experience in clinical research and development of on...

Leadership Team

NamePositionTenureCompensationOwnership
Jay Mei
Founder4.4yrsCN¥16.77m26%
€ 15.7m
Donald Andrew Lung
CFO & Executive Director4.6yrsCN¥7.12mno data
Eitan Liu
Chief Operating Officer4.4yrsno datano data
Shimin Sun
Corporate VP and Head of Clinical Enabling Functions & Operational Excellenceno datano datano data
Thomas Karalis
Corporate VP & Head of Asia Pacific Region4.8yrsno datano data
Dirk Hoenemann
VP and Head of Medical Affairs for APAC & Early Clinical Development4.5yrsno datano data
Xiaojing Zhang
Chief Medical Officer2.1yrsno datano data
Yang Cao
Joint Company Secretaryno datano datano data
Wai Chiu Wong
Joint Company Secretary2.8yrsno datano data

4.4yrs

Average Tenure

47yo

Average Age

Experienced Management: 722's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jay Mei
Founder6.4yrsCN¥16.77m26%
€ 15.7m
Donald Andrew Lung
CFO & Executive Director3.6yrsCN¥7.12mno data
Timothy M. Block
Member of Scientific Advisory Boardno datano datano data
Joseph Camardo
Member of Scientific Advisory Boardno datano datano data
Shaji K. Kumar
Member of Scientific Advisory Boardno datano datano data
Jeffrey Barrett
Member of Scientific Advisory Boardno datano datano data
Robert Gale
Member of Scientific Advisory Boardno datano datano data
Jing Qian
Independent Non-Executive Director4.2yrsCN¥487.00kno data
Sheng Tang
Independent Non-Executive Director4.2yrsCN¥487.00kno data
Rafael Fonseca
Independent Non-Executive Director1.8yrsCN¥193.00kno data
Florence Houn
Member of the Scientific Advisory Boardno datano datano data
Wei-Li Zhao
Member of Scientific Advisory Boardno datano datano data

4.2yrs

Average Tenure

57yo

Average Age

Experienced Board: 722's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 08:40
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Antengene Corporation Limited is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyu HeChina International Capital Corporation Limited
Wangbin ZhouCitigroup Inc
Ruili BianCitigroup Inc